Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)

    February 2012 in “Oncology Reports
    Nuha Ibrahim, Youcheng Yu, William R. Walsh, Jialin Yang
    Image of study
    TLDR Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
    The document reviews Sorafenib, an FDA-approved oral multikinase inhibitor for advanced renal cell carcinoma (RCC) and unresectable hepatocellular carcinoma (HCC). Sorafenib targets various kinases involved in tumor growth and angiogenesis and induces apoptosis. Its effectiveness as monotherapy is limited in some cancers due to resistance, leading to research into combination therapies with chemotherapy and radiation, which have shown promise. Clinical trials, including two phase III trials for HCC, have demonstrated significant improvements in overall survival and progression-free survival with Sorafenib. However, its activity is limited in cancers like melanoma and hormone refractory prostate cancer. Combination therapies have varied efficacy and tolerability, and ongoing research aims to optimize treatment regimens and identify appropriate biomarkers for patient selection to enhance Sorafenib's benefits.
    View this study on →